Public Knowledge of Human Papillomavirus and Receipt of Vaccination Recommendations-Reference-Cited by-同舟云学术

Public Knowledge of Human Papillomavirus and Receipt of Vaccination Recommendations

Published:2019-11-01 Issue:11 Volume:173 Page:1099
ISSN:2168-6203
Container-title:JAMA Pediatrics
language:en
Short-container-title:JAMA Pediatr

Author:

Suk Ryan¹,Montealegre Jane R.²,Nemutlu Gizem S.³,Nyitray Alan G.⁴,Schmeler Kathleen M.⁵,Sonawane Kalyani¹⁶,Deshmukh Ashish A.¹

Affiliation:

1. Center for Health Services Research, Department of Management, Policy and Community Health, UTHealth School of Public Health, Houston, Texas

2. Department of Pediatrics, Baylor College of Medicine, Houston, Texas

3. Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston

4. Clinical Cancer Center/Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee

5. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston

6. Center for Healthcare Data, Department of Management, Policy and Community Health, UTHealth School of Public Health, Houston, Texas

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology, and Child Health

Link

https://jamanetwork.com/journals/jamapediatrics/articlepdf/2749340/jamapediatrics_suk_2019_ld_190030.pdf

Reference5 articles.

1. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years: United States, 2017.;Walker;MMWR Morb Mortal Wkly Rep,2018

2. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature.;Holman;JAMA Pediatr,2014

3. Picking up the pace: changes in method and frame for the health information national trends survey (2011-2014).;Finney Rutten;J Health Commun,2012

4. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation.;Daley;Papillomavirus Res,2017

5. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [news release]. Silver Spring, MD: US Food & Drug Administration; October 5. 2018. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old?utm_campaign=10052018_PR_FDA+approves+expanded+use+of+Gardasil+9+to+include+individuals+27+through+45+years+old. Accessed August 7, 2019.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge of HPV vaccination and associated HNC and treatment decision-making among minority populations;American Journal of Otolaryngology;2024-11

2. Assessment of health literacy and HPV knowledge among university students: An observational study;Medicine;2024-08-30

3. Consumption of Health-Related Videos and Human Papillomavirus Awareness: Cross-Sectional Analyses of a US National Survey and YouTube From the Urban-Rural Context;Journal of Medical Internet Research;2024-01-15

4. Assessment of nanotoxicology through in vitro techniques and image-based assays;Molecular Pharmaceutics and Nano Drug Delivery;2024

5. A qualitative study of ethnic Korean women and men's experiences of HPV and HPV vaccination in the United States;Ethnicity & Health;2023-11-16